MORTON GROVE, Unwell., Dec. 13, 2021 (GLOBE NEWSWIRE) — Lifeway Meals, Inc. (Nasdaq: LWAY) (“Lifeway” or “the Firm”), the main U.S. producer of kefir and fermented probiotic merchandise to assist the microbiome, right now applauds the latest evaluate titled “The Rising State of affairs of the Intestine–Mind Axis: The Therapeutic Actions of the New Actor Kefir towards Neurodegenerative Ailments” printed in . The review examines the connection between disturbances in the gut microbiota and the progression of chronic neurodegenerative diseases, and how the protective and therapeutic effects of probiotics, such as those found in kefir, may play an instrumental role in slowing the progression of such diseases, which include Parkinson’s disease, Alzheimer’s disease, dementia, and epilepsy.
This review serves as a continuation of the research examining the anti-inflammatory effects of kefir’s probiotic cultures and peptides on the microbiome. While earlier studies have focused on the immune health benefits of probiotics, specifically their potential to protect against viral infections and help mitigate inflammatory conditions resulting from COVID-19, this most up-to-date evaluate takes a more in-depth take a look at the gut-brain axis and the way the anti-inflammatory and antioxidant properties may help stop neuronal degeneration related to the abovementioned continual neurodegenerative illnesses. Key findings from the evaluate embody:
Neurodegeneration has been related to irritation and its mediators, which collectively result in endothelial dysfunction, resulting in blood-brain barrier (BBB) disruption [44], apoptosis [221], necroptosis, [222,223], neuronal autophagy [224,225], and astrogliopathy [226] and accumulation of Aβ and tau protein [227,228]. These occasions related to reactive oxygen species (ROS) set off neurodegenerative occasions [227,229,230,231]The microbial composition of the gastrointestinal tract influences neuronal tissue by numerous pathways, corresponding to immune, neurological, and endocrine signaling [241,242], affecting habits, BBB integrity, neurogenesis, and neurotransmitter manufacturing [243]. In response to oxidative stress, intestine microbiota range is altered, which may even set off neuroinflammation and, consequently, neurodegeneration [244,245].Earlier proof factors to the anti-inflammatory and immunomodulatory potential of kefir. Problems related to irritation are a key reason for morbidity and mortality as a consequence of continual illnesses. Peptides from kefir inhibited the NF-κB signaling pathway [163], elevated anti-inflammatory (IL-10), and decreased the manufacturing of proinflammatory cytokines (corresponding to INF, IL-1β, IL-6, and TNF) [40,115,159,204,211].The probiotics in kefir had a attainable neuroprotective impact because of the modulation of the microbiota, which was related to diminished expression of inflammatory cytokines and ROS manufacturing, leading to much less cognitive injury [115]. The rise in these genera of micro organism proved to be an vital indicator of intestine microbiome reestablishment [250,294,295].Just lately, Olsson et al. (2020) [296] printed a big cohort research that included roughly 82,000 Swedish adults, and the outcomes confirmed the affiliation between milk consumption and an elevated threat of Parkinson’s illness (PD) (as beforehand noticed by others) [297,298]. In distinction, fermented milk (soured milk and yogurt) consumption was not related to an elevated threat of growing PD [298].
Whereas further analysis is required, Lifeway is inspired by the preliminary findings that place kefir as an accessible, food-based therapeutic therapy possibility for the hundreds of thousands of individuals worldwide affected by continual neurodegenerative illnesses.
“At Lifeway Meals, we’re persistently impressed and warranted by the unimaginable analysis across the microbiome’s results on general well being and the potential to assist folks reside more healthy, extra fulfilling lives by consuming fermented, probiotic meals and taking a proactive position in sustaining their intestine well being,” states Julie Smolyansky, CEO of Lifeway Meals, Inc. “As all the time, we proceed to salute these whose analysis builds upon the inspiration laid by Nobel Prize winner Élie Metchnikoff. We provide thanks and gratitude to the scientific neighborhood for his or her efforts to unlock life-changing breakthroughs although the modulation of intestine microbiota, and for serving to us unfold the phrase about the advantages of probiotics and kefir.”
Because the main U.S. provider of kefir, Lifeway Kefir is made with 12 lively cultures and full of protein, calcium and vitamin D. Every product is loaded with probiotics, which analysis suggests might assist to assist the microbiome. Moreover, analysis, such because the findings outlined above, means that probiotic merchandise corresponding to kefir might assist assist the physique’s response to lower irritation.
Lifeway Meals CEO Julie Smolyansky shall be discussing analysis and pure meals developments on December fifteenth on the Global Consumer Growth Conference offered by Wolfe Analysis. To study extra about Lifeway and its merchandise, go to lifewayfoods.com. To view the total evaluate printed in Antioxidants Quantity 10, go to MDPI.com.
About Lifeway Meals
Lifeway Meals, Inc., which has been acknowledged as certainly one of Forbes’ Finest Small Corporations, is America’s main provider of the probiotic, fermented beverage referred to as kefir. Along with its line of drinkable kefir, the corporate additionally produces cheese and a ProBugs line for youths. Lifeway’s tart and tangy fermented dairy merchandise are actually bought throughout the USA, Mexico, Eire, France and the UK. Find out how Lifeway is sweet for extra than simply you at lifewayfoods.com.
Ahead-Trying Statements
All statements on this launch (and oral statements made relating to the topics of this launch) comprises “forward-looking statements” as outlined within the Personal Securities Litigation Reform Act of 1995 relating to, amongst different issues, future working and monetary efficiency, product improvement, market place, enterprise technique and targets. These statements use phrases, and variations of phrases, corresponding to “anticipate,” “imaginative and prescient,” “will,” “predict,” “develop,” and “pattern.” Different examples of ahead wanting statements might embody, however usually are not restricted to, (i) statements of Firm plans and targets, together with the introduction of recent merchandise, or estimates or predictions of actions by clients or suppliers, (ii) statements of future financial efficiency, and (III) statements of assumptions underlying different statements and statements about Lifeway or its enterprise. You’re cautioned to not depend on these forward-looking statements. These statements are primarily based on present expectations of future occasions and thus are inherently topic to uncertainty. If underlying assumptions show inaccurate or identified or unknown dangers or uncertainties materialize, precise outcomes may range materially from Lifeway’s expectations and projections. These dangers, uncertainties, and different components embody: worth competitors; the choices of consumers or customers; the actions of rivals; adjustments within the pricing of commodities; the consequences of presidency regulation; attainable delays within the introduction of recent merchandise; and buyer acceptance of services and products. An additional listing and outline of those dangers, uncertainties, and different components may be present in Lifeway’s Annual Report on Kind 10-Ok for the fiscal 12 months ended December 31, 2020, and the Firm’s subsequent filings with the SEC. Copies of those filings can be found on-line at https://www.sec.gov, http://lifewaykefir.com/investor-relations/, or on request from Lifeway. Info on this launch is as of the dates and time intervals indicated herein, and Lifeway doesn’t undertake to replace any of the knowledge contained in these supplies, besides as required by regulation. Accordingly, YOU SHOULD NOT RELY ON THE ACCURACY OF ANY OF THE STATEMENTS OR OTHER INFORMATION CONTAINED IN ANY ARCHIVED PRESS RELEASE.
Contact:
Lifeway Meals, Inc.
Telephone: 847-967-1010
E mail: info@lifeway.net
References:
7. Friques, A.G.; Arpini, C.M.; Kalil, I.C.; Gava, A.L.; Leal, M.A.; Porto, M.L.; Nogueira, B.V.; Dias, A.T.; Andrade, T.U.; Pereira, T.M.; et al. Persistent administration of the probiotic kefir improves the endothelial perform in spontaneously hypertensive rats. J. Transl. Med. 2015, 13, 390.
14. Friques, A.G.F.; Santos, F.D.N.; Angeli, D.B.; Silva, F.A.C.; Dias, A.T.; Aires, R.; Leal, M.A.S.; Nogueira, B.V.; Amorim, F.G.; Campagnaro, B.P.; et al. Bisphenol A contamination in toddler rats: Molecular, structural, and physiological cardiovascular adjustments and the protecting position of kefir. J. Nutr. Biochem. 2020, 75, 108254.
40. Ton, A.M.M.; Campagnaro, B.P.; Alves, G.A.; Aires, R.; Côco, L.Z.; Arpini, C.M.; Guerra, E.O.T.; Campos-Toimil, M.; Meyrelles, S.S.; Pereira, T.M.C.; et al. Oxidative Stress and Dementia in Alzheimer’s Sufferers: Results of Synbiotic Supplementation. Oxid. Med. Cell. Longev. 2020, 2020, 2638703.
44. Vasquez, E.C.; Aires, R.; Ton, A.M.M.; Amorim, F.G. New Insights on the Helpful Results of the Probiotic Kefir on Vascular Dysfunction in Cardiovascular and Neurodegenerative Ailments. Curr. Pharm. Des. 2020, 26, 3700–3710.
63. Monteiro, B.L.; Dias, A.T.; Wanderkoke, S.C.; Yokota, R.; Casarini, D.E.; Leal, M.A.S.; Nogueira, B.V.; Meyrelles, S.S.; Campos-Toimil, M.; Campagnaro, B.P.; et al. Protecting results of kefir within the angiotensin II-dependent hypertension. J. Funct. Meals 2020, 75, 104260.
80. Santanna, A.F.; Filete, P.F.; Lima, E.M.; Porto, M.L.; Meyrelles, S.S.; Vasquez, E.C.; Endringer, D.C.; Lenz, D.; Abdalla, D.S.P.; Pereira, T.M.C.; et al. Persistent administration of the soluble, nonbacterial fraction of kefir attenuates lipid deposition in LDLr(-/-) mice. Vitamin 2017, 35, 100–105.
101. Barboza, Ok.R.M.; Coco, L.Z.; Alves, G.M.; Peters, B.; Vasquez, E.C.; Pereira, T.M.C.; Meyrelles, S.S.; Campagnaro, B.P. Gastroprotective impact of oral kefir on indomethacin-induced acute gastric lesions in mice: Impression on oxidative stress. Life Sci. 2018, 209, 370–376.
115. Lemos, V.R.; Aires, R.; Côco, L.Z.; Domingues, R.B.; Meyrelles, S.S.; Vasquez, E.C.; Pereira, T.M.C.; Campagnaro, B.P. Advantages of multi-day supplementation with probiotic kefir in Rasmussen encephalitis: The primary case report. Nutr. Neurosci. 2021, 1–8.
159. Vinderola, C.G.; Duarte, J.; Thangavel, D.; Perdigón, G.; Farnworth, E.; Matar, C. Immunomodulating capability of kefir. J. Dairy Res. 2005, 72, 195–202.
163. Chen, H.L.; Hung, Ok.F.; Yen, C.C.; Laio, C.H.; Wang, J.L.; Lan, Y.W.; Chong, Ok.Y.; Fan, H.C.; Chen, C.M. Kefir peptides alleviate particulate matter <4 μm (PM(4.0))-induced pulmonary irritation by inhibiting the NF-κB pathway utilizing luciferase transgenic mice. Sci. Rep. 2019, 9, 11529.
204. Carasi, P.; Racedo, S.M.; Jacquot, C.; Romanin, D.E.; Serradell, M.A.; Urdaci, M.C. Impression of kefir derived Lactobacillus kefiri on the mucosal immune response and intestine microbiota. J. Immunol. Res. 2015, 2015, 361604.
207. Fahmy, H.A.; Ismail, A.F.M. Gastroprotective impact of kefir on ulcer induced in irradiated rats. J. Photochem. Photobiol. B Biol. 2015, 144, 85–93.
208. Ghoneum, M.; Abdulmalek, S.; Pan, D. Reversal of age-associated oxidative stress in mice by PFT, a novel kefir product. Int. J. Immunopathol. Pharmacol. 2020, 34, 2058738420950149.
209. Ali, O.S.M.; Amin, N.E.; Abdel Fattah, S.M.; Abd El-Rahman, O. Ameliorative impact of kefir towards γ-irradiation induced liver damage in male rats: Impression on oxidative stress and irritation. Environ. Sci. Pollut. Res. Int. 2020, 27, 35161–35173.
210. Punaro, G.R.; Maciel, F.R.; Rodrigues, A.M.; Rogero, M.M.; Bogsan, C.S.; Oliveira, M.N.; Ihara, S.S.; Araujo, S.R.; Sanches, T.R.; Andrade, L.C.; et al. Kefir administration diminished development of renal damage in STZ-diabetic rats by reducing oxidative stress. Nitric Oxide 2014, 37, 53–60.
211. Rosa, D.D.; Grześkowiak, Ł.M.; Ferreira, C.L.; Fonseca, A.C.; Reis, S.A.; Dias, M.M.; Siqueira, N.P.; Silva, L.L.; Neves, C.A.; Oliveira, L.L.; et al. Kefir reduces insulin resistance and inflammatory cytokine expression in an animal mannequin of metabolic syndrome. Meals Funct. 2016, 7, 3390–3401.
221. Ghavami, S.; Shojaei, S.; Yeganeh, B.; Ande, S.R.; Jangamreddy, J.R.; Mehrpour, M.; Christoffersson, J.; Chaabane, W.; Moghadam, A.R.; Kashani, H.H.; et al. Autophagy and apoptosis dysfunction in neurodegenerative issues. Prog. Neurobiol. 2014, 112, 24–49.
222. Degterev, A.; Huang, Z.; Boyce, M.; Li, Y.; Jagtap, P.; Mizushima, N.; Cuny, G.D.; Mitchison, T.J.; Moskowitz, M.A.; Yuan, J. Chemical inhibitor of nonapoptotic cell loss of life with therapeutic potential for ischemic mind damage. Nat. Chem. Biol. 2005, 1, 112–119.
223. Ofengeim, D.; Ito, Y.; Najafov, A.; Zhang, Y.; Shan, B.; DeWitt, J.P.; Ye, J.; Zhang, X.; Chang, A.; Vakifahmetoglu-Norberg, H.; et al. Activation of necroptosis in a number of sclerosis. Cell Rep. 2015, 10, 1836–1849.
224. Pickford, F.; Masliah, E.; Britschgi, M.; Lucin, Ok.; Narasimhan, R.; Jaeger, P.A.; Small, S.; Spencer, B.; Rockenstein, E.; Levine, B.; et al. The autophagy-related protein beclin 1 exhibits diminished expression in early Alzheimer illness and regulates amyloid beta accumulation in mice. J. Clin. Investig. 2008, 118, 2190–2199.
225. Hara, T.; Nakamura, Ok.; Matsui, M.; Yamamoto, A.; Nakahara, Y.; Suzuki-Migishima, R.; Yokoyama, M.; Mishima, Ok.; Saito, I.; Okano, H.; et al. Suppression of basal autophagy in neural cells causes neurodegenerative illness in mice. Nature 2006, 441, 885–889.
226. Kovacs, G.G.; Robinson, J.L.; Xie, S.X.; Lee, E.B.; Grossman, M.; Wolk, D.A.; Irwin, D.J.; Weintraub, D.; Kim, C.F.; Schuck, T.; et al. Evaluating the Patterns of Growing old-Associated Tau Astrogliopathy Unravels Novel Insights into Mind Growing old and Neurodegenerative Ailments. J. Neuropathol. Exp. Neurol. 2017, 76, 270–288.
227. Liu, Z.; Li, T.; Li, P.; Wei, N.; Zhao, Z.; Liang, H.; Ji, X.; Chen, W.; Xue, M.; Wei, J. The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer’s Illness. Oxid. Med. Cell. Longev. 2015, 2015, 352723.
228. Silva, I.; Silva, J.; Ferreira, R.; Trigo, D. Glymphatic system, AQP4, and their implications in Alzheimer’s illness. Neurol. Res. Pract. 2021, 3, 5.
229. Angelova, P.R.; Abramov, A.Y. Position of mitochondrial ROS within the mind: From physiology to neurodegeneration. FEBS Lett. 2018, 592, 692–702.
230. Dawson, T.M.; Dawson, V.L. Nitric Oxide Signaling in Neurodegeneration and Cell Loss of life. Adv. Pharmacol. 2018, 82, 57–83.
231. Marogianni, C.; Sokratous, M.; Dardiotis, E.; Hadjigeorgiou, G.M.; Bogdanos, D.; Xiromerisiou, G. Neurodegeneration and Irritation-An Fascinating Interaction in Parkinson’s Illness. Int. J. Mol. Sci. 2020, 21, 8421.
241. Burokas, A.; Moloney, R.D.; Dinan, T.G.; Cryan, J.F. Microbiota regulation of the Mammalian gut-brain axis. Adv. Appl. Microbiol. 2015, 91, 1–62.
242. Ochoa-Repáraz, J.; Mielcarz, D.W.; Begum-Haque, S.; Kasper, L.H. Intestine, bugs, and mind: Position of commensal micro organism within the management of central nervous system illness. Ann. Neurol. 2011, 69, 240–247.
243. Luczynski, P.; McVey Neufeld, Ok.A.; Oriach, C.S.; Clarke, G.; Dinan, T.G.; Cryan, J.F. Rising up in a Bubble: Utilizing Germ-Free Animals to Assess the Affect of the Intestine Microbiota on Mind and Habits. Int. J. Neuropsychopharmacol. 2016, 19, pyw020.
244. Ley, R.E.; Hamady, M.; Lozupone, C.; Turnbaugh, P.J.; Ramey, R.R.; Bircher, J.S.; Schlegel, M.L.; Tucker, T.A.; Schrenzel, M.D.; Knight, R.; et al. Evolution of mammals and their intestine microbes. Science 2008, 320, 1647–1651.
245. Goldman, J.G.; Postuma, R. Premotor and nonmotor options of Parkinson’s illness. Curr. Opin. Neurol. 2014, 27, 434–441.
250. Yáñez, M.; Viña, D. Twin inhibitors of monoamine oxidase and cholinesterase for the therapy of Alzheimer illness. Curr. Prime. Med. Chem. 2013, 13, 1692–1706.
294. Passos, M.; Moraes-Filho, J.P. INTESTINAL MICROBIOTA IN DIGESTIVE DISEASES. Arq. Gastroenterol. 2017, 54, 255–262.
295. Strati, F.; Cavalieri, D.; Albanese, D.; De Felice, C.; Donati, C.; Hayek, J.; Jousson, O.; Leoncini, S.; Renzi, D.; Calabrò, A.; et al. New evidences on the altered intestine microbiota in autism spectrum issues. Microbiome 2017, 5, 24.
296. Olsson, E.; Byberg, L.; Höijer, J.; Kilander, L.; Larsson, S.C. Milk and Fermented Milk Consumption and Parkinson’s Illness: Cohort Examine. Vitamins 2020, 12, 2763.
297. Chen, H.; O’Reilly, E.; McCullough, M.L.; Rodriguez, C.; Schwarzschild, M.A.; Calle, E.E.; Thun, M.J.; Ascherio, A. Consumption of dairy merchandise and threat of Parkinson’s illness. Am. J. Epidemiol. 2007, 165, 998–1006.
298. Hughes, Ok.C.; Gao, X.; Kim, I.Y.; Wang, M.; Weisskopf, M.G.; Schwarzschild, M.A.; Ascherio, A. Consumption of dairy meals and threat of Parkinson illness. Neurology 2017, 89, 46–52.
299. Swanson, Ok.S.; Gibson, G.R.; Hutkins, R.; Reimer, R.A.; Reid, G.; Verbeke, Ok.; Scott, Ok.P.; Holscher, H.D.; Azad, M.B.; Delzenne, N.M.; et al. The Worldwide Scientific Affiliation for Probiotics and Prebiotics (ISAPP) consensus assertion on the definition and scope of synbiotics. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 687–701.
